lutikizumab
Sponsor Abbvie INC. · listed as ABBV
READOUT
Phase 3
Confidence: medium
Source: clinicaltrials
lutikizumab is a clinical-stage drug asset sponsored by Abbvie INC., listed as ABBV. CSA tracks 1 forward catalyst for it — the nearest is a readout expected Dec 2026 (month precision, medium confidence), tied to trial NCT06468228. The asset is in Phase 3 and currently active not recruiting, studied in Hidradenitis Suppurativa.
Next catalyst
Event typeREADOUT
Expected date2026-12-31
As disclosedDec 2026
Date precisionmonth
Confidencemedium
Trial & sponsor
Trial (NCT)NCT06468228
PhasePHASE3
StatusACTIVE_NOT_RECRUITING
Lead sponsorAbbVie
Listed asABBV
Condition(s)Hidradenitis Suppurativa
!
Data, not investment advice. CSA is information, not a recommendation to buy, sell or hold any security. Estimated catalyst dates routinely slip and are graded by confidence — verify against the source link before acting.
This is one row of the free CSA sample. The full snapshot carries 2,103 forward catalysts across 139 listed sponsors.
Get the full dataset — $499 → More ABBV catalysts